These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 24731853)

  • 1. Maximising survival: the main concern of women with hereditary breast and ovarian cancer who undergo genetic testing for BRCA1/2.
    Jeffers L; Morrison PJ; McCaughan E; Fitzsimons D
    Eur J Oncol Nurs; 2014 Aug; 18(4):411-8. PubMed ID: 24731853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Living with genetic test results for hereditary breast and ovarian cancer.
    Hamilton R; Williams JK; Skirton H; Bowers BJ
    J Nurs Scholarsh; 2009; 41(3):276-83. PubMed ID: 19723276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "It's not if I get cancer, it's when I get cancer": BRCA-positive patients' (un)certain health experiences regarding hereditary breast and ovarian cancer risk.
    Dean M
    Soc Sci Med; 2016 Aug; 163():21-7. PubMed ID: 27376595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
    Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
    Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
    Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
    JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "It was an Emotional Baby": Previvors' Family Planning Decision-Making Styles about Hereditary Breast and Ovarian Cancer Risk.
    Dean M; Rauscher EA
    J Genet Couns; 2017 Dec; 26(6):1301-1313. PubMed ID: 28138923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer.
    Hallowell N; Foster C; Eeles R; Ardern-Jones A; Watson M
    Soc Sci Med; 2004 Aug; 59(3):553-65. PubMed ID: 15144764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
    Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
    Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision-making on preimplantation genetic diagnosis and prenatal diagnosis: a challenge for couples with hereditary breast and ovarian cancer.
    Derks-Smeets IA; Gietel-Habets JJ; Tibben A; Tjan-Heijnen VC; Meijer-Hoogeveen M; Geraedts JP; van Golde R; Gomez-Garcia E; van den Bogaart E; van Hooijdonk M; de Die-Smulders CE; van Osch LA
    Hum Reprod; 2014 May; 29(5):1103-12. PubMed ID: 24603131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic genetic testing for hereditary breast and ovarian cancer in cancer patients: women's looking back on the pre-test period and a psychological evaluation.
    Claes E; Evers-Kiebooms G; Boogaerts A; Decruyenaere M; Denayer L; Legius E
    Genet Test; 2004; 8(1):13-21. PubMed ID: 15140370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterizing biased cancer-related cognitive processing: relationships with BRCA1/2 genetic mutation status, personal cancer history, age, and prophylactic surgery.
    Carpenter KM; Eisenberg S; Weltfreid S; Low CA; Beran T; Stanton AL
    Health Psychol; 2014 Sep; 33(9):1003-11. PubMed ID: 23772886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.
    Tong A; Kelly S; Nusbaum R; Graves K; Peshkin BN; Valdimarsdottir HB; Wood M; McKinnon W; Garber J; McCormick SR; Jandorf L; Schwartz MD
    Psychooncology; 2015 Jan; 24(1):33-9. PubMed ID: 24839250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families.
    Lynch HT; Snyder C; Lynch JF; Karatoprakli P; Trowonou A; Metcalfe K; Narod SA; Gong G
    Cancer Genet Cytogenet; 2006 Mar; 165(2):91-7. PubMed ID: 16527602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit finding in response to BRCA1/2 testing.
    Low CA; Bower JE; Kwan L; Seldon J
    Ann Behav Med; 2008 Feb; 35(1):61-9. PubMed ID: 18347905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cognitive, emotional and behavioral impact of an uncertain outcome after study of BRCA1/2: review of the literature].
    Leblond D; Brédart A; Dolbeault S; De Pauw A; Stoppa Lyonnet D; Flahault C; Sultan S
    Bull Cancer; 2011 Feb; 98(2):184-98. PubMed ID: 21382771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing.
    Lodder L; Frets PG; Trijsburg RW; Klijn JG; Seynaeve C; Tilanus MM; Bartels CC; Meijers-Heijboer EJ; Verhoog LC; Niermeijer MF
    Am J Med Genet A; 2003 Jun; 119A(3):266-72. PubMed ID: 12784290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.
    Werner-Lin A; Hoskins LM; Doyle MH; Greene MH
    Health (London); 2012 Nov; 16(6):636-54. PubMed ID: 22547552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "When information is not enough": A model for understanding BRCA-positive previvors' information needs regarding hereditary breast and ovarian cancer risk.
    Dean M; Scherr CL; Clements M; Koruo R; Martinez J; Ross A
    Patient Educ Couns; 2017 Sep; 100(9):1738-1743. PubMed ID: 28385363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.